evipedia.ai
← Back

Riboflavin for Health & Longevity

Created on 11/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Riboflavin (vitamin B2), an essential vitamin sold as a dietary supplement, aids energy production and folate and vitamin B6 processing. High doses for about three months appear to reduce adult migraine frequency, resting mostly on one trial. Low doses lowered blood pressure in carriers of two copies of a common folate-gene variant; an independent review judged this very uncertain. Oral risks are minimal; benefits in well-supplied people are uncertain. (Full Review)

Protocol

High-dose mitochondrial approach (Schoenen)
400 mg/day
For at least three months for migraine; doses above about 27 mg exceed single-dose absorption, so splitting high doses is logical
Genotype-targeted approach (Ulster group, McNulty)
1.6 mg/day
For 16 weeks in MTHFR 677TT carriers; genotype testing identifies them
Nutritional adequacy
1.3 mg/day men; 1.1 mg/day women
US recommended intake, usually met by dairy, eggs, meat and fortified grains
Time to effect
Migraine prevention
3 months
Migraine trials assessed effects after three months
Blood pressure
Within 16 weeks
In MTHFR 677TT carriers
Riboflavin status
Within 8–12 weeks
Biochemical status improves

Benefits

Contraindications
  • Pregnant women (corneal cross-linking only)
  • People with a known riboflavin allergy (oral riboflavin)
    •
Key Interactions
  • Probenecid
  • Anticholinergic drugs (propantheline, oxybutynin)
  • Oral contraceptives (ethinyl estradiol combinations)
  • Folic acid supplements
  • Vitamin B6
  • Antihypertensive drugs (ramipril, bendroflumethiazide, amlodipine)
  • Magnesium and coenzyme Q10
    •
Theoretical (inferred from mechanism)
  • Tricyclic antidepressants (amitriptyline, imipramine) and phenothiazines (chlorpromazine)
  • Doxorubicin
  • Heavy alcohol intake
  • Over-the-counter anticholinergic antihistamines (diphenhydramine, doxylamine)
    •

Risk & Side Effects

  • Low: Gastrointestinal upset and frequent urination at high doses; bright yellow urine; posterior subcapsular cataract with riboflavin plus niacin; corneal haze, eye pain and keratitis after cross-linking; anaphylaxis
    •
  • Speculative: Photosensitization; tumor growth support
    •

Monitoring

Marker Target Why
EGRAC (erythrocyte glutathione reductase activation coefficient) 1.26 or lower Confirms improved riboflavin status
Blood pressure Below 140/90 mmHg Expected to change in MTHFR 677TT carriers
Plasma homocysteine Below 7–8 µmol/L Expected to change in TT carriers with low status
Hemoglobin Women 12.0–15.5 g/dL; men 13.5–17.5 g/dL Expected to change in marginal deficiency
Plasma PLP (pyridoxal 5'-phosphate) No established target; track change from own baseline Riboflavin activates vitamin B6
MTHFR 677C>T genotype Not specified in the ER One-time test; decides whether low-dose use is relevant

Cadence: Baseline EGRAC before starting; repeat EGRAC and any abnormal baseline marker at 3 months, then every 6–12 months during long-term use. Home blood pressure weekly for the first month in TT carriers taking antihypertensives, then monthly. Migraine diary for one month before starting and through the three-month trial.

Qualitative Assessment

  • Migraine days, attack duration and pain severity per month (diary)
  • Need for acute migraine medication
  • Energy levels and exercise recovery
  • Lip and tongue soreness or cracks at the mouth corners (signs of deficiency)
  • Dizziness on standing in those taking antihypertensives
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.